• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The Daily Dose: Adult RSV Vaccine


Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study.

The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On October 14, 2022, we reviewed a pivotal phase 3 clinical trial of an investigational respiratory syncytial virus (RSV) vaccine (RSVPreF3 OA) for older adults.

The study

The phase 3 randomized placebo-controlled AReSVi-006 trial enrolled 25 000 participants from 17 countries to evaluate efficacy of a single dose of the adjuvanted RSVPreF3 OA investigational vaccine in adults aged ≥60 years. Findings, which will be presented at IDWeek 2002 later this month, showed overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease, satisfying the trial’s primary endpoint.

A note from the manufacturer

“These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research,” said GSK chief scientific officer Tony Wood in a statement.

The company believes that these robust findings suggest the potential for RSVPreF3 OA to help reduce the global burden of RSV-LRTD, and particularly among older and the most vulnerable adults.

Click here for the full study review.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
© 2024 MJH Life Sciences

All rights reserved.